The answer to the question in the title: Without a doubt, 100%, absolutely, a solid probably.
Unfortunately, we can't get any more confident than that. This is the Food and Drug Administration we're talking about here.
Before Amylin Pharmaceuticals'
While I'll plant my flag in the camp expecting an approval, I'd caution investors not to go all-in here. It's not unprecedented for minor issues to trip up companies multiple times. Worse yet, we've seen the FDA come up with new issues even after having another six months to review the drug.
That still seems relevant 15 months later. Amylin appears to have crossed all its t's and dotted all its i's -- some that didn't need to be written in the first place -- but that seemed to be the case last time, too. The first rejection was for minor risk management and manufacturing issues; the second was for potential heart problems the drug might cause that weren't brought up in the first rejection. I have a hard time seeing either of those getting in the way of an approval, but there's just no way to know if the FDA can come up with something else to harass Amylin about. The risk is low, but an approval isn't guaranteed, either.
It's not just Amylin that has a stake in Bydureon's approval; both Eli Lilly
That's my take. How do you size up Bydureon's chances of gaining an approval on its third shot? Take the poll and tell us your reasoning in the comment box below.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
Find out which big American pharma is best suited to provide big gains in the years to come.
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Worry about whether drug pricing will return to the forefront in Washington, D.C. is increasing following Donald Trump's nomination of a drug-industry insider as his next Department of Health and Human Services secretary.